Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Metab ; 35(8): 1341-1355.e3, 2023 08 08.
Article in English | MEDLINE | ID: mdl-37433299

ABSTRACT

GDF15 regulates its anorexic effects through the hindbrain area postrema (AP) and nucleus of the solitary tract (NTS) neurons where its receptor, glial-derived neurotrophic factor receptor alpha-like (GFRAL), is expressed. The actions of GDF15 may interact with other appetite regulators elevated in obesity, such as leptin. Here, we report that in mice with high-fat-diet-induced obesity (HFD), the combined infusion of GDF15 and leptin causes significantly greater weight and adiposity loss than either treatment alone, indicating potentiation between GDF15 and leptin. Furthermore, obese, leptin-deficient ob/ob mice are less responsive to GDF15, as are normal mice treated with a competitive leptin antagonist. GDF15 and leptin induce more hindbrain neuronal activation in HFD mice than either treatment alone does. We report extensive connections between GFRAL- and LepR-expressing neurons and find LepR knockdown in the NTS to reduce the GDF15-mediated activation of AP neurons. Overall, these findings suggest that leptin signaling pathways in the hindbrain increase GDF15's metabolic actions.


Subject(s)
Adiposity , Leptin , Animals , Mice , Body Weight , Leptin/pharmacology , Leptin/metabolism , Mice, Obese , Obesity/metabolism , Receptors, Leptin/metabolism , Solitary Nucleus/metabolism
2.
Growth Factors ; 29(5): 187-95, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21831009

ABSTRACT

Macrophage inhibitory cytokine-1 (MIC-1/GDF15) is associated with cardiovascular disease, inflammation, body weight regulation and cancer. Its serum levels facilitate the diagnosis and prognosis of cancer and vascular disease. Furthermore, its serum levels are a powerful predictor of all-cause mortality, suggesting a fundamental role in biological processes associated with ageing. In cancer, the data available suggest that MIC-1/GDF15 is antitumorigenic, but this may not always be the case as disease progresses. Cancer promoting effects of MIC-1/GDF15 may be due, in part, to effects on antitumour immunity. This is suggested by the anti-inflammatory and immunosuppressive properties of MIC-1/GDF15 in animal models of atherosclerosis and rheumatoid arthritis. Furthermore, in late-stage cancer, large amounts of MIC-1/GDF15 in the circulation suppress appetite and mediate cancer anorexia/cachexia, which can be reversed by monoclonal antibodies in animals. Available data suggest MIC-1/GDF15 may be an important molecule mediating the interplay between cancer, obesity and chronic inflammation.


Subject(s)
Growth Differentiation Factor 15/metabolism , Inflammation/metabolism , Neoplasms/metabolism , Aging , Animals , Anorexia/metabolism , Anorexia/therapy , Biomarkers , Cachexia/metabolism , Cachexia/therapy , Cardiovascular Diseases/metabolism , Cell Line, Tumor , Disease Progression , Growth Differentiation Factor 15/blood , Humans , Mice , Neoplasms/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...